News
Imaging biomarker may help to better understand and treat progressive multiple sclerosis
A research work led by neuroradiologists and neurologists from IDIBELL, the Bellvitge University Hospital, and the Institute of Diagnostic Imaging identified a new magnetic resonance biomarker. This biomarker would make it possible to accurately detect the focus of chronic brain inflammation, associated with the progressive form of multiple sclerosis.
First clinical trial of a treatment that attacks lung cancer and brain metastasis at the same time
In a phase 2 clinical trial, researchers have observed that this combination allows to carry out global treatment from the beginning, manages to keep metastases stable for 7
IDIBELL participates in EU-funded ONCODIR project to improve colorectal cancer prevention
Led by the Centre for Research and Technology Hellas (CERTH), the project includes 27 complementary partners from different research domains. This initiative integrates cutting-edge research methodologies powered by artificial intelligence to deliver personalized, evidence-based approaches for preventing this type of cancer.
A meta-analysis by IDIBELL and Bellvitge Hospital examines the use of beta-lactam antibiotics in febrile neutropenia
The results of five studies have been reviewed, two of them randomized clinical trials, with a total of 691 episodes of febrile neutropenia. The effects of the use of beta-lactam antibiotics in intermittent infusions have been compared with prolonged infusions.
New research will look for risk indicators of harmful internet use among adolescents
Dr. Josep Manuel Menchon, group leader at IDIBELL and head of the Psychiatry Service at Bellvitge University Hospital, participates in a pioneering study led by the University of Hertfordshire to address and reduce the risks of harmful Internet use among adolescents.
Maria Eulàlia Juvé and Jordi Adamuz participate in the publication of a nursing mentoring book
The article by Juvé and Adamuz highlights the importance of knowledge of nursing tools and strategies (ATIC and ARES) to improve patient outcomes and the work environment.
The IDIBELL educational Tandem with the Institut Bellvitge closes the 2022-23 academic year with the launch of new activities
The participation of Institute students in the IDIBELL sLHam for women scientists, the creation of a new Sant Jordi award or the co-creation of content and activities for the new Biomedicine subject have been the main novelties of the course.
A new neuroprotective drug shows good preliminary results for ischemic stroke
According to the results of the APRIL study, in which the Hospital de Bellvitge and IDIBELL have participated, ApTOLL has shown good safety in 151 patients with acute ischemic stroke.
Another year at IDIBELL we maintain our commitment to research, training and innovation to improve people’s health
In 2022, with almost 1,500 published articles, of which almost 600 were led by IDIBELL researchers, our research maintained its high level of quality and excellence, with an average impact factor greater than nine.